Proton pump inhibitors and gastric neoplasia.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 16905689.
- Also identified by PMC identifier 1860013.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Proton pump inhibitors (PPIs) are very effective in maintaining symptomatic and endoscopic remission of acid peptic disorders, such as gastro-oesophageal reflux disease. Side effects with respect to function and morphology of the gastric mucosa are common. Helicobacter pylori eradication can partially prevent and reverse these effects without impairing PPI therapy for gastro-oesophageal reflux disease. This makes long term PPI treatment a safe therapy for patients with acid peptic disorders. The potential side effects of such therapy are discussed here.
Medical subject headings
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Stomach Neoplasms